Background New-onset diabetes after transplant (NODAT) is one of the metabolic complications of kidney transplant surgery. The incident of NODAT varies highly, from 5% up to 53%. Some factors increase the risk for NODAT, such as age, gender, immunosuppressant drugs, among others. The progressivity of NODAT leads to increased cardiovascular risks, making the identification of risk factors crucial.
BACKGROUND
Chronic kidney disease (CKD) is a global health problem with continually increasing incidence and prevalence and poor outcome, causing a high financial burden. According to the World Health Organization and Burden of Diseases, kidney and urinary tract diseases were responsible for 85,000 of annual death. 1 Data from the Indonesian Society of Nephrology reported 12.5% or about 25 million of the Indonesian population have declining renal function or CKD. 2 In over 600,000 patients with end-stage renal disease (ESRD) in the United States, a kidney transplant is considered as the most optimum therapy to date. The procedure has been linked to a higher survival rate, better quality of life, and overall lower cost compared to dialysis. 3 New-onset diabetes after transplant (NODAT) is defined as diabetes that occurred in patients after kidney transplant without a prior history of diabetes. 4, 5 NODAT is one of the least studied complications of kidney transplantation. In a few studies using new immunosuppressant regimen, the prevalence of NODAT is up to 20%. 6 Diabetes Mellitus (DM) diagnosed after patients underwent organ transplantation is reported in 4% -25% of patients with renal transplantation, 2.5% -25% of patients with liver transplant and 2% -53% of patients with other solid organ transplants. 7 NODAT increases cardiovascular risks and complication risks such as infection. Moreover, the increase of mortality rate and graft rejection were also found to be associated with NODAT. 8 Risk factors for the development of NODAT can be categorized as non-modifiable and probable modifiable risk factors (Table 1 ). The interaction between risk factors and its relation to the development of NODAT is presented in Figure 2 . Because NODAT is linked to poor prognosis in kidney transplant patients, identifying the risk factors for NODAT is of great value. The knowledge will be used to implement preventive measures to decrease the morbidity and mortality rate of kidney transplant patients. Data regarding NODAT risk factors in Indonesia are not yet widely available, therefore this study aimed to identify the risk factors of NODAT in the Indonesian population.
Risk Factors for New-Onset Diabetes After Transpant in Kidney Transplant Recipients

METHODS
Patients
Secondary data from medical records were obtained from a private nephrology clinic in Surabaya, consisting of non-diabetic CKD patients who have undergone kidney transplant surgery throughout January 1998 -August 2015 and received immunosuppressant regimen of calcineurin inhibi-tors (CNI), mycophenolate mofetil (MMF), and methylprednisolone (MP). Medical records not containing adequate clinical information were excluded. A total of 56 patients were found eligible for the study.
Data Collection
Data related to NODAT risk factors collected were age, gender, history of hypertriglyceridemia, type of CNI drug received, history of hypertension, and familial history of diabetes. NODAT is defined using diagnostic criteria for diabetes mellitus from the American Diabetes Association (2014) in the range of three months after kidney transplantation.
Statistical Analysis
Data were analyzed statistically using SPSS 22 nd version.
Qualitative data were presented in the form of sums and percentages, whereas quantitative data were presented as mean values and standard deviations (X ± SD). Bivariate analysis using cross tab is used for categorical data and using unpaired T-test or Mann-Whitney. Variables with p < 0.25 were analyzed using multivariate analysis of logistic regression. Threshold for significant p-value is < 0.05 with 95% confidence interval. 
RESULT
DISCUSSION
NODAT was first discovered in 1964 from liver transplant patients of Thomas Starz, which developed 6 months after surgery and receiving immunosuppressant therapy. The rate of diabetes in these patients was 6% annually. 11 The rate of NODAT incidence varies, depending on the type of organ transplanted, time of follow-up, diagnostic criteria, and immunosuppressant drugs used.
The pathophysiology of NODAT includes the diabetogenic effect of corticosteroids, which is dose-dependent.
A prospective study on 173 kidney-transplant patients, an increase of prednisolone dosage 0.01 mg/kg/day is related to a 5% increase in diabetes mellitus. 6 Corticosteroid was found to alter glucose metabolism by increasing liver glucose production and decreasing insulin sensitivity. Insulin resistance and relative insulin deficiency were suggested to be the main cause of diabetes due to steroid use. Steroid discontinuation protocol showed decreased insulin resistance and increased glucose metabolism in kidney transplant patients. 12 Decreased insulin secretion was considered as the main contributing factor of calcineurin inhibitors' diabetogenic effect. An experimental study showed calcineurin inhibitors' effect in insulin gene expression of pancreatic beta-cells. Pancreas biopsy showed a relationship between pancreatic islet cells and the blood concentration of tacrolimus and cyclosporine. 9 The prevalence of NODAT in this study was 32.1%. In a study by Vincenti et al, the prevalence of NODAT 6 months after kidney transplant was 20.5%, whereas the study by Woodward et al found 24.8% of NODAT prevalence. 11, 13 In this study, the only risk factor found nearing statistical significance was the age of > 60 years old (p=0.055) similar to study results by Shah et al. Other risk factors that were found clinically significant but not statistically significant were male gender (p=0.068), consistent to study results conducted by Pham et al. 9 and the use of tacrolimus (p=0.093). Clinical trials assessing the effects of tacrolimus and cyclosporine administration in transplant patients showed varying results, but mostly showing higher diabetogenic effects of tacrolimus. Data from the United States showed the incidence of NODAT 2 years after transplant was higher in patients receiving tacrolimus (30%) compared to those receiving cyclosporine (18%), suggesting the use of tacrolimus as a risk factor for NODAT compared to cyclosporine. 11 Familial history of diabetes was found to be a risk factor for NODAT in a study by Hjelsmeeth et al. 6 In this study however, no relationship was found between family history of diabetes with increased risk for NODAT.
This study has numerous limitations including the small sample size and the use of secondary data from medical records. The sample was also obtained from one private clinic with no regards to the place of surgery. Better recording system and centralization of transplant procedure to one dedicated health center are important to give comprehensive management to transplant patients. Future research should include samples from multiple centers to give a better representation of patients and increase the statistical power of the study.
CONCLUSION
This study found patients' age of over 60 years old, male gender, and the use of tacrolimus in the immunosuppressive regimen to be a clinically significant but not statistically significant risk factor for NODAT. Bigger multicenter studies with a higher amount of subjects are needed to assess the risk factors of NODAT.
